W
WAVEMAN · COMPANY
AKBA · Akebia Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AKBA

Akebia Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001517022
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$62.2K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+47.5%
XBRL, annual
NET MARGIN
-2.3%
CONVERSIONS · 180D
1
codes C/M, not in net · $220.5K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$62.2K over 180 days
-$62.2K over 90 days
more than 58% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+47.5% year over year
more than 78% of Pharma & Biotech
MARGIN
-2.3% net margin
more than 64% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
6.9% of shares outstanding short · 8.8 days to cover · settled 2026-07-31
more than 65% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -68.7%
-68.7%12M
-73%-48%-23%+2%2025-092025-102025-122026-032026-052026-072026-09 2026-02-02 · Butler John P. sold $159.7K2026-02-02 · Butler John P. sold $133.5K2026-02-02 · Butler John P. sold $116.3K2026-03-04 · Butler John P. bought $86.6K2026-02-02 · Grund Nicholas sold $74.5K2026-02-02 · Butler John P. sold $64.9K2026-06-29 · Ostrowski Erik sold $62.2K2026-02-02 · Malabre Richard C sold $50.2K2026-02-02 · Ostrowski Erik sold $48.6K2026-02-02 · Grund Nicholas sold $43.4K2026-02-02 · Rucci Carolyn M. sold $38.3K2026-02-02 · Rucci Carolyn M. sold $35.3K2026-02-02 · Burke Steven Keith sold $35.3K2026-02-02 · Burke Steven Keith sold $30.0K2026-02-02 · Burke Steven Keith sold $28.8K2026-02-02 · Rucci Carolyn M. sold $23.4K2026-02-02 · Malabre Richard C sold $18.6K2026-06-29 · Ostrowski Erik filed to sell $62.2K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $62.2K sold by insiders over 180 days, $62.2K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Akebia Therapeutics, Inc. insiders sold a net $62.2K of stock across 88 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Ostrowski Erik
SVP, CFO, CBO & Treasurer
SELL
2026-06-29
56,019.0
$62.2K
Butler John P.
CEO and President
BUY
2026-03-04
69,270.0
$86.6K
Malabre Richard C
SVP, Chief Accounting Officer
SELL
2026-02-02
13,382.0
$18.6K
Malabre Richard C
SVP, Chief Accounting Officer
SELL
2026-02-02
36,142.0
$50.2K
Grund Nicholas
Chief Commercial Officer
SELL
2026-02-02
53,585.0
$74.5K
88 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 83 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Ostrowski Erik
FILED 2026-06-29
$62.2K
Clinical pipeline
ClinicalTrials.gov · 8 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
2
Phase 2
2 ACTIVE
5
Phase 3
0 ACTIVE
What changed recently
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of
2026-09-05 · Completion moved 2026-08 → 2026-08-12
Phase 3
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of
2026-09-05 · Active Not Recruiting → Completed
Phase 3
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Akebia Therapeutics Inc Political Action Committee
CYCLE 2026 · $16K SPENT
$11.0K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · John P. Butler
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$5.7M
$4.2M
$1.8M
-42%
+25%
2024
$4.3M
$5.6M
$1.4M
-32%
-7%
2023
$2.8M
$4.5M
$1.2M
-56%
-6%
2022
$3.1M
$707.6K
$1.4M
-79%
-10%
2021
$3.1M
$2.4M
$1.4M
-19%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$236.2M$160.2M$194.6M$292.5M
OPERATING INCOME$23.5M$-50.5M$-46.3M$-80.8M
NET INCOME$-5.3M$-69.4M$-51.9M$-94.2M
EPS (DILUTED)-0.02-0.33-0.28-0.52
OPERATING CASH FLOW$68.0M$-40.7M$-23.4M$-73.2M
CASH$184.8M$51.9M$42.9M$90.5M
LONG-TERM DEBT$48.2M$38.7M$17.2M$34.1M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →